Immunological and virological response to fostemsavir in routine US clinical care: An <scp>OPERA</scp> cohort study
After 6 or 12 months of fostemsavir use, virological response was low in viraemic individuals, although most suppressed individuals did maintain suppression. While immunological response varied across individuals, virologically suppressed HTE individuals with low CD4 counts may benefit from immunological improvements with fostemsavir.
Authors
- Jennifer S Fusco (ORCID: https://orcid.org/0000-0003-1556-811X)
- Philip C. Lackey
- Brooke Levis (ORCID: https://orcid.org/0000-0002-4310-3689)
- Gerald Pierone (ORCID: https://orcid.org/0000-0003-0159-7243)
- Cassidy Henegar (ORCID: https://orcid.org/0000-0002-4566-1174)
- Laurence Brunet (ORCID: https://orcid.org/0000-0001-8467-4835)
- Vani Vannappagari (ORCID: https://orcid.org/0000-0002-0157-9689)
- Gregory Fusco (ORCID: https://orcid.org/0000-0002-6834-784X)
- Andrew Clark (ORCID: https://orcid.org/0000-0002-0272-4788)
- Ricky K Hsu
Institutions
- AIDS Healthcare Foundation (US)
- NYU Langone Health (US)
- Oyster Point Family Health Center (US)
- GridBridge (United States) (US)
- Wake Forest University (US)
Publication Details
- Journal
- HIV Medicine
- Published
- 2024-08-25
- DOI
- https://doi.org/10.1111/hiv.13700
- Citations
- 2
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 0.78
Funders
- ViiV Healthcare